How We Think - Genetics

These are the posts from the How we think section that have been tagged with Genetics.

To see all tags used in our posts, click here.

How do you define a biotech company?

David Cooney | 6th October 2017

We ask if the defnition of biotech needs updating as big pharma turns its research and development aims to biological therapies.

read more

Emerging technologies in biotech

Ditte Funding, Natasha Cowan | 25th September 2017

Associate Consultant Ditte Funding and Content Marketing Executive Natasha Cowan explore the transformative technologies revolutionising the biotech industry, from CAR-T to CRISPR.

read more

Perspective on biotech

Blue Latitude Health | 14th September 2017

In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating

read more

target-precision-medicine-healthcare-professional-darts

Precision medicine and the changing role of the healthcare professional

Ditte Funding | 23rd March 2017

The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of the healthcare professional (HCP) in the patient journey? Associate Consultant Ditte Funding discusses challenges and opportunities.

read more

runway-sea-sky_Blue-Latitude-Health

The 2017 trends issue of Perspective magazine is live

Blue Latitude Health | 9th January 2017

In the 2017 trends edition of Perspective magazine, we explore how advances in technology are influencing the future of the expert-patient relationship and the role healthcare businesses can take in supporting and enhancing these interactions at the point of need.

read more

genomic-data-visualised-creative-commons-image-blue-latitude-health

What pharma needs to know about genomic data in 2016

David Cooney | 3rd February 2016

About ten years ago, personalised medicine was a major step forward – tailoring treatments based on individual patient history and information. Fast forward to 2015, and investigating the central dogma of biology is still a major focus of healthcare research. 

Consultant David Cooney talks us through what this progress in genomics means for pharma in 2016.

read more

WIRED-Health-2015-Blue-Latitude-Health

WIRED Health 2015: Key themes and takeaways

Blue Latitude Health | 14th May 2015

James and David from the Blue Latitude Health Strategy team attended WIRED Health 2015, and reported back on what they thought the most exciting and relevant takeaways were for pharma and marketing.

read more

microscope-dna-Blue-Latitude-Health-biomarkers-in-marketing

Use of biomarkers in marketing

Mark Assenti | 12th March 2015

The modern pharmaceutical market can be saturated with competing products, from bio-similars, to same in-class, to alternative MoA treatments. Standing out from the crowd can be tough; innovative and patient serving methods of differentiation are hard to come by. 

Consultant Mark Assenti talks through the use of biomarkers in pharma marketing and where it's headed in 2015.

read more

lightbulb-dna-photo

Is the future of pharma marketing in our DNA?

Mark Assenti | 17th February 2014

Customer data is collected and used by almost every marketing department globally to better target audiences, so is it now time to take the next step, and add DNA to the pharma marketing mix? Mark Assenti explores the ethical and scientific issues behind genetic marketing.

read more